{"id":"degarelix","rwe":[],"_fda":{"id":"4c6e7e6f-aadd-45b1-baed-970b24766bf3","set_id":"ab11dd8a-0fd9-4013-89ab-e114557c7e4b","openfda":{"rxcui":["828749","828751","858125","858127"],"spl_id":["4c6e7e6f-aadd-45b1-baed-970b24766bf3"],"brand_name":["FIRMAGON"],"spl_set_id":["ab11dd8a-0fd9-4013-89ab-e114557c7e4b"],"package_ndc":["55566-8403-1","55566-8303-1"],"product_ndc":["55566-8303","55566-8403"],"generic_name":["DEGARELIX"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Ferring Pharmaceuticals Inc."],"application_number":["NDA022201"],"is_original_packager":[true]},"version":"18","pregnancy":["8.1 Pregnancy Risk Summary The safety and efficacy of FIRMAGON have not been established in women. Based on findings in animal studies and mechanism of action, FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]. There are no human data on the use of FIRMAGON in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicity studies in rats and rabbits, oral administration of degarelix during organogenesis caused embryo-fetal lethality and abortion as well as increased post-implantation loss and decreased the number of live fetuses in animals at doses less than the clinical loading dose based on body surface area ( see Data ). Advise pregnant patients and females of reproductive potential of the potential risk to the fetus. Data Animal Data When degarelix was given to rabbits during early organogenesis at doses of 0.002 mg/kg/day (about 0.02% of the clinical loading dose based on body surface area), there was an increase in early post-implantation loss. Degarelix given to rabbits during mid and late organogenesis at doses of 0.006 mg/kg/day (about 0.05% of the clinical loading dose based on body surface area) caused embryo/fetal lethality and abortion. When degarelix was given to female rats during early organogenesis, at doses of 0.0045 mg/kg/day (about 0.036% of the clinical loading dose based on body surface area), there was an increase in early post-implantation loss. When degarelix was given to female rats during mid and late organogenesis, at doses of 0.045 mg/kg/day (about 0.36% of the clinical loading dose based on body surface area), there was an increase in the number of minor skeletal abnormalities and variants."],"overdosage":["10 OVERDOSAGE There have been no reports of overdose with FIRMAGON. In the case of overdose, however, discontinue FIRMAGON, treat the patient symptomatically, and institute supportive measures."],"description":["11 DESCRIPTION FIRMAGON is a sterile lyophilized powder for injection containing degarelix (as the acetate) and mannitol. Degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids. The acetate salt of degarelix is a white to off-white amorphous powder of low density as obtained after lyophilization. The chemical name of degarelix is D-Alaninamide, N -acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl- N 6–(1-methylethyl)-L-lysyl-L-prolyl. It has an empirical formula of C 82 H 103 N 18 O 16 Cl and a molecular weight of 1632.3 Da. Degarelix acetate has the following structural formula: FIRMAGON is available in two packaging configurations: Starting Dose: Two vial carton with each vial delivering 120 mg of degarelix (equivalent to the median value of 126 mg degarelix acetate). Each 120 mg dose contains 150 mg mannitol. Maintenance Dose: One-vial carton delivering 80 mg of degarelix (equivalent to the median value of 84 mg degarelix acetate). Each 80 mg dose contains 200 mg mannitol. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING FIRMAGON is available as: NDC 55566-8403-1, Starting dose – One carton contains: Two single-dose vials each delivering 120 mg of degarelix in a white to off-white lyophilized powder for injection Two prefilled syringes each containing 3 mL of Sterile Water for Injection, USP Two vial adapters Two administration needles NDC 55566-8303-1, Maintenance dose – One carton contains: One single-dose vial delivering 80 mg of degarelix in a white to off-white lyophilized powder for injection One prefilled syringe containing 4.2 mL of Sterile Water for Injection, USP One vial adapter One administration needle Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Of the total number of subjects in clinical studies of FIRMAGON, 82% were age 65 and over, while 42% were age 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20240130","clinical_studies":["14 CLINICAL STUDIES The safety and efficacy of FIRMAGON were evaluated in an open-label, multi-center, randomized, parallel-group study (NCT00295750) in patients with prostate cancer. A total of 620 patients were randomized to receive one of two FIRMAGON dosing regimens or leuprolide for one year: a. FIRMAGON at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 80 mg (20 mg/mL) subcutaneously, b. leuprolide 7.5 mg intramuscularly monthly. c. FIRMAGON at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 160 mg (40 mg/mL) subcutaneously. FIRMAGON is not approved for use with monthly doses of 160 mg (40 mg/mL) subcutaneously. Serum levels of testosterone were measured at screening, on Day 0, 1, 3, 7, 14, and 28 in the first month, and then monthly until the end of the study. The clinical trial population (n=610) across all treatment arms had an overall median age of approximately 73 (range 50 to 98). The ethnic/racial distribution was 84% white, 6% black and 10% others. Disease stage was distributed approximately as follows: 20% metastatic, 29% locally advanced (T3/T4 Nx M0 or N1 M0), 31% localized (T1 or T2 N0 M0) and 20% classified as other (including patients whose disease metastatic status could not be determined definitively - or patients with PSA relapse after primary curative therapy). In addition, the median testosterone baseline value across treatment arms was approximately 400 ng/dL. The primary objective was to demonstrate that FIRMAGON is effective achieving and maintaining testosterone suppression to castration levels (T ≤ 50 ng/dL) during 12 months of treatment. The results are shown in Table 3. Table 3: Medical Castration Rates (Testosterone ≤ 50 ng/dL) from Day 28 to Day 364 FIRMAGON 240/80 mg N=207 Leuprolide 7.5 mg N=201 No. of Responders 202 194 Castration Rate (95% CIs) Kaplan Meier estimates within group 97.2% (93.5; 98.8) 96.4% (92.5; 98.2) Percentage changes in testosterone from baseline to Day 28 (median with interquartile ranges) are shown in Figure 2 and the percentages of patients who attained the medical castration of testosterone ≤ 50 ng/dL are summarized in Table 4. Figure 2: Percentage Change in Testosterone from Baseline by Treatment Group until Day 28 (Median with Interquartile Ranges) Table 4: Percentage of Patients Attaining Testosterone ≤ 50 ng/dL within the First 28 Days FIRMAGON 240/80 mg N=207 Leuprolide 7.5 mg N=201 Day 1 52% 0% Day 3 96% 0% Day 7 99% 1% Day 14 99% 18% Day 28 100% 100% In the clinical trial, PSA levels were monitored as a secondary endpoint. PSA levels were lowered by 64% two weeks after administration of FIRMAGON, 85% after one month, 95% after three months, and remained suppressed throughout the one year of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit. Figure 2"],"pharmacodynamics":["12.2 Pharmacodynamics A single dose of 240 mg FIRMAGON causes a decrease in the plasma concentrations of luteinizing hormone (LH) and follicle stimulating hormone (FSH), and subsequently testosterone. FIRMAGON is effective in achieving and maintaining testosterone suppression below the castration level of 50 ng/dL. Figure 1: Plasma Testosterone Levels from Day 0 to 364 for Degarelix 240 mg/80 mg (Median with Interquartile Ranges) Figure 1"],"pharmacokinetics":["12.3 Pharmacokinetics Absorption FIRMAGON forms a depot upon subcutaneous administration, from which degarelix is released to the circulation. Following administration of FIRMAGON 240 mg at a product concentration of 40 mg/mL, the mean Cmax was 26.2 ng/mL (coefficient of variation, CV 83%) and the mean AUC was 1054 ng∙day/mL (CV 35%). Typically Cmax occurred within 2 days after subcutaneous administration. In prostate cancer patients at a product concentration of 40 mg/mL, the pharmacokinetics of degarelix were linear over a dose range of 120 to 240 mg. The pharmacokinetic behavior of the drug is strongly influenced by its concentration in the injection solution. Distribution The distribution volume of degarelix after intravenous (> 1 L/kg) or subcutaneous administration (> 1000L) indicates that degarelix is distributed throughout total body water. In vitro plasma protein binding of degarelix is estimated to be approximately 90%. Metabolism Degarelix is subject to peptide hydrolysis during the passage of the hepato-biliary system and is mainly excreted as peptide fragments in the feces. No quantitatively significant metabolites were detected in plasma samples after subcutaneous administration. In vitro studies have shown that degarelix is not a substrate, inducer or inhibitor of the CYP450 or p-glycoprotein transporter systems. Excretion Following subcutaneous administration of 240 mg FIRMAGON at a concentration of 40 mg/mL to prostate cancer patients, degarelix is eliminated in a biphasic fashion, with a median terminal half-life of approximately 53 days. The long half-life after subcutaneous administration is a consequence of a very slow release of degarelix from the FIRMAGON depot formed at the injection site(s). Approximately 20-30% of a given dose of degarelix was renally excreted, suggesting that approximately 70-80% is excreted via the hepato-biliary system in humans. Following subcutaneous administration of degarelix to prostate cancer patients the clearance is approximately 9 L/hr. Effect of Age, Weight and Race There was no effect of age, weight or race on the degarelix pharmacokinetic parameters or testosterone concentration."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions (≥10%) are injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. FIRMAGON was studied in a randomized, open-label trial in which patients with prostate cancer were randomized to receive FIRMAGON (subcutaneous) or leuprolide (intramuscular) monthly for 12 months [see Clinical Studies (14) ] . The most common adverse reactions (≥10%) during FIRMAGON therapy are injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT). The majority of the adverse reactions were Grade 1 or 2, with Grade 3/4 adverse reaction incidences of 1% or less. Adverse reactions reported in ≥ 5% of patients treated with FIRMAGON (subcutaneous) 240 mg starting dose and then 80 mg maintenance dose once every 28 days or who were treated with 7.5 mg of leuprolide (intramuscular) every 28 days are shown in Table 2. Table 2: Adverse Reactions Reported in ≥ 5% of Patients FIRMAGON 240/80 mg (subcutaneous) N = 207 Leuprolide 7.5 mg (intramuscular) N = 201 Any adverse reaction 79% 78% Body as a whole Injection site reactions Includes pain, erythema, swelling, induration, or nodule. 35% <1% Weight increase 9% 12% Chills 5% 0% Cardiovascular system Hot flash 26% 21% Hypertension 6% 4% Digestive system Increases in Transaminases and GGT 10% 5% Constipation 5% 5% Musculoskeletal system Back pain 6% 8% Arthralgia 5% 9% Urogenital system Urinary tract infection 5% 9% The following adverse reactions occurred in 1 to < 5% of patients treated with FIRMAGON: Body as a whole: Asthenia, fatigue, fever, night sweats Digestive system: Nausea Nervous system: Dizziness, headache, insomnia The following adverse reactions, not already listed, occurred in ≥ 1% of patients treated in any study with FIRMAGON: Reproductive System: Erectile dysfunction, testicular atrophy Endocrine Disorders: Gynecomastia General : Hyperhidrosis Gastrointestinal : Diarrhea Injection Site Reactions The most frequently reported adverse reactions at the injection sites were pain (28%), erythema (17%), swelling (6%), induration (4%) and nodule (3%). These adverse reactions were mostly transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 injection site reactions occurred in 2% or less of patients receiving FIRMAGON. Hepatic Laboratory Abnormalities Hepatic laboratory abnormalities were primarily Grade 1 or 2 and were generally reversible. Grade 3 hepatic laboratory abnormalities occurred in less than 1% of patients. FIRMAGON Extension Study The safety of FIRMAGON administered once every 28 days was evaluated further in an extension study (NCT00451958) in 385 patients who completed the above active-controlled trial. Of the 385 patients, 251 patients continued treatment with FIRMAGON and 135 patients crossed over treatment from leuprolide to FIRMAGON. The median treatment duration on the extension study was approximately 43 months (range 1 to 58 months). The most common adverse reactions reported in ≥10% of the patients were injection site reactions (e.g., pain, erythema, swelling, induration or inflammation), pyrexia, hot flush, weight loss or gain, fatigue, increases in serum levels of hepatic transaminases and GGT. One percent of patients had injection site infections including abscess. Hepatic laboratory abnormalities in the extension study included the following: Grade 1/2 elevations in hepatic transaminases occurred in 47% of patients and Grade 3 elevations occurred in 1% of patients. 6.2 Immunogenicity As with all peptides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. Anti-Degarelix Antibodies Anti-degarelix antibody development has been observed in 10% of patients after treatment with FIRMAGON for 1 year. There is no indication that the efficacy or safety of FIRMAGON treatment is affected by antibody formation. 6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval use of FIRMAGON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Changes in bone density Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with a GnRH agonist. It can be anticipated that long periods of medical castration in men will result in decreased bone density."],"contraindications":["4 CONTRAINDICATIONS FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components [see Warnings and Precautions (5.1) ] . Patients with history of severe hypersensitivity reactions to degarelix or to any of the product components ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No drug-drug interaction studies were conducted. Degarelix is not a substrate for the human CYP450 system. Degarelix is not an inducer or inhibitor of the CYP450 system in vitro . Therefore, clinically significant CYP450 pharmacokinetic drug-drug interactions are unlikely."],"mechanism_of_action":["12.1 Mechanism of Action Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone."],"recent_major_changes":["Warnings and Precautions, Embryo-Fetal Toxicity ( 5.4 ) 02/2020"],"storage_and_handling":["Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Degarelix is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. 12.2 Pharmacodynamics A single dose of 240 mg FIRMAGON causes a decrease in the plasma concentrations of luteinizing hormone (LH) and follicle stimulating hormone (FSH), and subsequently testosterone. FIRMAGON is effective in achieving and maintaining testosterone suppression below the castration level of 50 ng/dL. Figure 1: Plasma Testosterone Levels from Day 0 to 364 for Degarelix 240 mg/80 mg (Median with Interquartile Ranges) Figure 1 12.3 Pharmacokinetics Absorption FIRMAGON forms a depot upon subcutaneous administration, from which degarelix is released to the circulation. Following administration of FIRMAGON 240 mg at a product concentration of 40 mg/mL, the mean Cmax was 26.2 ng/mL (coefficient of variation, CV 83%) and the mean AUC was 1054 ng∙day/mL (CV 35%). Typically Cmax occurred within 2 days after subcutaneous administration. In prostate cancer patients at a product concentration of 40 mg/mL, the pharmacokinetics of degarelix were linear over a dose range of 120 to 240 mg. The pharmacokinetic behavior of the drug is strongly influenced by its concentration in the injection solution. Distribution The distribution volume of degarelix after intravenous (> 1 L/kg) or subcutaneous administration (> 1000L) indicates that degarelix is distributed throughout total body water. In vitro plasma protein binding of degarelix is estimated to be approximately 90%. Metabolism Degarelix is subject to peptide hydrolysis during the passage of the hepato-biliary system and is mainly excreted as peptide fragments in the feces. No quantitatively significant metabolites were detected in plasma samples after subcutaneous administration. In vitro studies have shown that degarelix is not a substrate, inducer or inhibitor of the CYP450 or p-glycoprotein transporter systems. Excretion Following subcutaneous administration of 240 mg FIRMAGON at a concentration of 40 mg/mL to prostate cancer patients, degarelix is eliminated in a biphasic fashion, with a median terminal half-life of approximately 53 days. The long half-life after subcutaneous administration is a consequence of a very slow release of degarelix from the FIRMAGON depot formed at the injection site(s). Approximately 20-30% of a given dose of degarelix was renally excreted, suggesting that approximately 70-80% is excreted via the hepato-biliary system in humans. Following subcutaneous administration of degarelix to prostate cancer patients the clearance is approximately 9 L/hr. Effect of Age, Weight and Race There was no effect of age, weight or race on the degarelix pharmacokinetic parameters or testosterone concentration."],"indications_and_usage":["1 INDICATIONS AND USAGE FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity: Anaphylaxis, urticaria and angioedema have been reported. Discontinue FIRMAGON if a severe hypersensitivity reaction occurs and manage as clinically indicated ( 5.1 ) QT Interval Prolongation: Androgen deprivation therapy treatment with FIRMAGON may prolong the QT interval. ( 5.2 ) Embryo-Fetal Toxicity: FIRMAGON can cause fetal harm. ( 5.4 , 8.1 ) 5.1 Hypersensitivity Reactions FIRMAGON is contraindicated in patients with history of severe hypersensitivity to degarelix or to any of the product components [see Contraindications (4) ]. Hypersensitivity reactions, including anaphylaxis, urticaria and angioedema, have been reported post-marketing with FIRMAGON. In case of a severe hypersensitivity reaction, discontinue FIRMAGON immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of severe hypersensitivity reactions to FIRMAGON should not be re-challenged with FIRMAGON. 5.2 QT Interval Prolongation Androgen deprivation therapy may prolong the QT interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. In the randomized, active-controlled trial comparing FIRMAGON to leuprolide, periodic electro-cardiograms were performed. Seven patients, three (<1%) in the pooled degarelix group and four (2%) patients in the leuprolide 7.5 mg group, had a QTcF ≥ 500 msec. From baseline to end of study, the median change for FIRMAGON was 12.3 msec and for leuprolide was 16.7 msec. 5.3 Laboratory Testing FIRMAGON results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after FIRMAGON may be affected. The therapeutic effect of FIRMAGON should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured. 5.4 Embryo-Fetal Toxicity Based on findings in animal studies, FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman. In animal developmental and reproductive toxicity studies in rats and rabbits, oral administration of degarelix during organogenesis caused embryo-fetal lethality and abortion as well as increased post-implantation loss and decreased the number of live fetuses in animals at doses less than the clinical loading dose based on body surface area. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus [see Use in Specific Populations (8.1) ]."],"clinical_studies_table":["
Table 3: Medical Castration Rates (Testosterone ≤ 50 ng/dL) from Day 28 to Day 364
FIRMAGON 240/80 mg N=207Leuprolide 7.5 mg N=201
No. of Responders202194
Castration Rate (95% CIs)Kaplan Meier estimates within group97.2% (93.5; 98.8)96.4% (92.5; 98.2)
","
Figure 2: Percentage Change in Testosterone from Baseline by Treatment Group until Day 28 (Median with Interquartile Ranges)
","
Table 4: Percentage of Patients Attaining Testosterone ≤ 50 ng/dL within the First 28 Days
FIRMAGON 240/80 mg N=207Leuprolide 7.5 mg N=201
Day 152%0%
Day 396%0%
Day 799%1%
Day 1499%18%
Day 28100%100%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Degarelix was administered subcutaneously to rats every 2 weeks for 2 years at doses of 2, 10 and 25 mg/kg (about 9, 45 and 120% of the recommended human loading dose on a mg/m 2 basis). Long term treatment with degarelix at 25 mg/kg caused an increase in the combined incidence of benign hemangiomas plus malignant hemangiosarcomas in females. Degarelix was administered subcutaneously to mice every 2 weeks for 2 years at doses of 2, 10 and 50 mg/kg (about 5, 22 and 120% of the recommended human loading dose (240 mg) on a mg/m 2 basis). There was no statistically significant increase in tumor incidence associated with this treatment. Degarelix did not cause genetic damage in standard in vitro assays (bacterial mutation, human lymphocyte chromosome aberration) nor in in vivo rodent bone marrow micronucleus tests. Single degarelix doses of ≥ 1 mg/kg (about 5% of the clinical loading dose on a mg/m 2 basis) caused reversible infertility in male rats. Single doses of ≥ 0.1 mg/kg (about 0.5% of the clinical loading dose on a mg/m 2 basis) caused a decrease in fertility in female rats."],"pharmacodynamics_table":["
Figure 1: Plasma Testosterone Levels from Day 0 to 364 for Degarelix 240 mg/80 mg (Median with Interquartile Ranges)
"],"adverse_reactions_table":["
Table 2: Adverse Reactions Reported in ≥ 5% of Patients
FIRMAGON 240/80 mg (subcutaneous) N = 207Leuprolide 7.5 mg (intramuscular) N = 201
Any adverse reaction79%78%
Body as a whole
Injection site reactionsIncludes pain, erythema, swelling, induration, or nodule.35%<1%
Weight increase9%12%
Chills5%0%
Cardiovascular system
Hot flash26%21%
Hypertension6%4%
Digestive system
Increases in Transaminases and GGT10%5%
Constipation5%5%
Musculoskeletal system
Back pain6%8%
Arthralgia5%9%
Urogenital system
Urinary tract infection5%9%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Hypersensitivity Inform patients that if they have experienced severe hypersensitivity with degarelix or to any of the product components, FIRMAGON is contraindicated [see Contraindications (4) ]. Instruct patients to immediately report signs of a severe hypersensitivity reaction [see Warnings and Precautions (5.1) ]. QT Interval Prolongation Advise patients that androgen deprivation therapy treatment with FIRMAGON may prolong the QT interval. Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation [see Warnings and Precautions (5.2) ]. Androgen Deprivation Inform patients about adverese reactions related to androgen deprivation therapy with FIRMAGON, including hot flashes, flushing of the skin, increased weight, decreased sex drive, and difficulties with erectile function [see Adverse Reactions (6.1) ] . Injection Site Reactions Inform patients that FIRMAGON may cause redness, swelling, and itching at the injection site. Advise patients that these adverse reactions are usually mild, self limiting, and decrease within three days [see Adverse Reactions (6.1) ] . Infertility Inform patients that FIRMAGON may cause infertility [see Use in Specific Populations (8.3) ]."],"spl_unclassified_section":["MANUFACTURED FOR: FERRING PHARMACEUTICALS INC., PARSIPPANY, NJ 07054 Manufactured in Germany 02/2020"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION FIRMAGON is for subcutaneous use only Starting Dosage: 240 mg given as two injections of 120 mg each ( 2.1 ) Maintenance Dosage: 80 mg administered as a single injection every 28 days ( 2.1 ) 2.1 Dosing information FIRMAGON is administered as a subcutaneous injection in the abdominal region only at the dosages in Table 1 below. Table 1: FIRMAGON Recommended Dosages Starting Dosage Maintenance Dosage – Administered once every 28 days 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL The first maintenance dose should be given 28 days after the starting dose. 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL 2.2 Reconstitution and Administration Instructions FIRMAGON is to be administered by a healthcare professional only . Before administering FIRMAGON read the Instructions for reconstitution and administration carefully. As with other drugs administered by subcutaneous injection, the injection site should vary periodically. Injections should be given only in areas of the abdomen that will not be exposed to pressure, e.g., not close to waistband or belt nor close to the ribs. FIRMAGON is supplied as a powder to be reconstituted with Sterile Water for Injection, USP. Starting dose (240 mg): Two single-dose vials each delivering 120 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in two prefilled syringes. Each vial is to be reconstituted with a prefilled syringe containing 3 mL of Sterile Water for Injection. 3 mL is withdrawn to deliver 120 mg degarelix at a concentration of 40 mg/mL. Maintenance dose (80 mg): One single-dose vial delivering 80 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in one prefilled syringe. Each vial is to be reconstituted with a prefilled syringe containing 4.2 mL of Sterile Water for Injection. 4 mL is withdrawn to deliver 80 mg degarelix at a concentration of 20 mg/mL. Follow the instructions for reconstitution closely and read the complete instructions before performing the subcutaneous injection. Reconstituted drug must be administered within one hour after addition of Sterile Water for Injection, USP. Do not shake the vials. Follow aseptic technique. FIRMAGON 240 mg Starting Dose Kit contains: 2 vials containing the 120 mg FIRMAGON powder (a) 2 syringes containing Sterile Water for Injection, USP (b) 2 vial adapters (c) 2 25 gauge × 1 inch injection needles (d) 2 plunger rods (e) FIRMAGON 80 mg Maintenance Dose Kit contains: 1 vial containing the 80 mg FIRMAGON powder (f) 1 syringe containing Sterile Water for Injection, USP (g) 1 vial adapter (h) 1 25 gauge × 1 inch injection needle (i) 1 plunger rod (j) In addition the healthcare professional will need: gloves (k) alcohol pads (l) a clean, flat surface (m) to work on, like a table a sharps disposal container (n) for throwing away your used needles and syringes. See \" Disposing used needles and syringes \" at the end of these instructions. The drug product must be prepared using the following instructions: NOTE: The mixing process must be repeated for the two injections of the Starting Dose prior to injecting the product into the patient's abdomen. Step 1: Attaching the vial adaptor to the vial Thoroughly wash your hands using soap and water and put on a pair of clean gloves. Place all the supplies required on a clean surface. Check that there is powder in the FIRMAGON vial and that the Sterile Water for Injection, USP is clear and free from particles. IMPORTANT: DO NOT USE if there is no powder in the vial or the Sterile Water for Injection, USP is discolored. Uncap the vial containing the FIRMAGON powder (o). Wipe the vial rubber stopper with an alcohol pad. IMPORTANT: Do not touch the top of the vial after wiping. Peel off the seal from the vial adaptor cover. IMPORTANT: Do not touch the vial adapter. Firmly press the vial adaptor (p) onto the vial containing the FIRMAGON powder until the adaptor snaps into place. Pull the vial adaptor cover off the vial. Step 2: Assembling the syringe Insert the plunger rod (q) into the prefilled syringe containing Sterile Water for Injection, USP (r) and screw the plunger rod clockwise to tighten. IMPORTANT: Do not pull the back stopper (flange) (s) off the syringe. NOTE: You will only feel light resistance screwing the plunger rod in position. Step 3: Transferring Sterile Water for Injection, USP from the syringe to the vial Unscrew the gray syringe plug (t) attached to the Luer lock adaptor on the syringe. IMPORTANT: Do not pull off the Luer lock adaptor (u). Carefully twist the prefilled syringe containing Sterile Water for Injection, USP onto the vial adapter on the FIRMAGON powder vial, until it is tight. IMPORTANT: Be careful not to over twist the syringe. Press the plunger slowly to transfer all the Sterile Water for Injection, USP from the syringe to the FIRMAGON powder vial. Step 4: Preparing the reconstituted injection With the syringe still attached to the vial adaptor, swirl gently until the liquid is clear with no powder or visible particles . IMPORTANT: Do not shake the vial as this will cause bubbles. Reconstitute just prior to administration. NOTE : If the powder adheres to the side of the vial, tilt the vial slightly. A ring of small air bubbles on the surface of the liquid is acceptable. Reconstitution time can take up to 15 min but usually takes a few minutes. Step 5: Transferring the liquid to the syringe Turn the vial completely upside down and pull down the plunger to withdraw all of the reconstituted liquid from the vial to the syringe. Tap the syringe gently with your fingers to raise air bubbles in the syringe tip. Press the plunger to the line marked on the syringe to expel all air bubbles. Step 6: Preparing the syringe for injection Holding the vial adaptor detach the syringe from the vial by unscrewing the syringe from the vial adaptor. NOTE : Reconstitute just prior to administration . While holding the syringe with the tip pointing up, screw the injection needle (v) clockwise (right) onto the syringe. Step 7: Preparing the patient Select one of the four available injection sites on the abdomen. IMPORTANT: Do not inject in areas where the patient will be exposed to pressure, such as area around the belt of the waistband or close to the ribs. Vary the injection site periodically during treatment to minimize discomfort to the patient. Clean the injection site with an alcohol pad. Step 8: Performing the injection Move the needle shield (w) away from the needle and carefully remove the needle cover (x). Pinch and elevate the skin of the abdomen. Insert the needle into the skin at a 45 degree angle all the way to the hub . Do not inject into a vein or muscle. Gently pull back the plunger to check if blood is aspirated. IMPORTANT: If blood appears in the syringe, the product should not be injected. Discontinue the injection and discard the syringe and the needle (reconstitute a new dose for the patient). Perform a slow , deep subcutaneous injection over 30 seconds. Remove the needle and then release the skin. IMPORTANT: Do not rub the injection site after retracting the needle. Step 9: Locking the needle into the shield Position the needle shield approximately 45 degrees to a flat surface. Press down with a firm, quick motion until a distinct, audible \"click\" is heard. Visually confirm that the needle is fully engaged under the lock (y). IMPORTANT: Syringe is for single use only. Do not reuse the syringe and needle . Step 10: Advising the patient Instruct the patient not to rub or scratch the injection site. Inform that some patients may feel a lump at the injection site and experience redness, soreness and discomfort for a few days after the injection. Disposing used needles and syringes Put used alcohol swabs, needles and syringes in an FDA-cleared sharps disposal container right away after use. Do not throw away loose needles and syringes in the trash. For more information about safe sharps disposal, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal. Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure Figure"],"spl_product_data_elements":["FIRMAGON Degarelix FIRMAGON Degarelix MANNITOL DEGARELIX DEGARELIX STERILE WATER Water WATER FIRMAGON Degarelix FIRMAGON Degarelix MANNITOL DEGARELIX DEGARELIX STERILE WATER Water WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS For injection: FIRMAGON (240 mg): Two single-dose vials each delivering 120 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in two prefilled syringes. FIRMAGON (80 mg): One single-dose vial delivering 80 mg of degarelix in a white to off-white lyophilized powder for reconstitution supplied with diluent in one prefilled syringe. For injection: FIRMAGON (240 mg): Two single-dose vials each delivering 120 mg of degarelix in a lyophilized powder for reconstitution supplied with diluent in two prefilled syringes ( 3 ) FIRMAGON (80 mg): One single-dose vial delivering 80 mg of degarelix in a lyophilized powder for reconstitution supplied with diluent in one prefilled syringe ( 3 )"],"recent_major_changes_table":["
Warnings and Precautions, Embryo-Fetal Toxicity (5.4)02/2020
"],"spl_patient_package_insert":["Patient Information FIRMAGON (FIRM-uh-gahn) (degarelix for injection) What is FIRMAGON? FIRMAGON is a prescription medicine used in the treatment of advanced prostate cancer. It is not known if FIRMAGON is safe or effective in children. Who should not receive FIRMAGON? Do not receive FIRMAGON if you are allergic to degarelix or any ingredient in FIRMAGON. See the end of this leaflet for a complete list of ingredients in FIRMAGON. Talk to your healthcare provider before receiving FIRMAGON if you have any of these conditions. Before receiving FIRMAGON, tell your healthcare provider about all your medical conditions, including if you: have any heart problems including a condition called long QT syndrome. have problems with blood levels such as sodium, potassium, calcium, and magnesium have kidney or liver problems are pregnant or plan to become pregnant. FIRMAGON can cause harm to your unborn baby and loss of pregnancy (miscarriage) are breastfeeding or plan to breastfeed. It is not known if FIRMAGON passes into your breast milk. You and your healthcare provider should decide if you will receive FIRMAGON or breastfeed. You should not do both. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How will I receive FIRMAGON? You will receive an injection of FIRMAGON from your healthcare provider. The injection site will always be in the stomach (abdominal area). The injection site will change within the stomach area each time you receive a dose of FIRMAGON. Two injections are given as a first dose. The following monthly doses are one injection. Do not rub or scratch the injection site. Make sure your injection site is free of any pressure from belts, waistbands or other types of clothing. Always set up an appointment for your next injection. What are the possible side effects of FIRMAGON? FIRMAGON can cause serious side effects, including: Serious allergic reactions. Get medical help right away if you get any of these symptoms: trouble breathing or wheezing severe itching swelling of your face, lips, mouth, or tongue Disorder of the heart's electrical activity. Your healthcare provider may do tests during treatment with FIRMAGON to check your heart for a condition called long QT syndrome. The common side effects of FIRMAGON include: injection site pain, redness, and swelling hot flashes weight gain increase in some liver enzymes Other side effects include decreased sex drive and erectile function problems. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of FIRMAGON. Medicines are sometimes prescribed for conditions that are not mentioned in a Patient Information leaflet. Do not use FIRMAGON for a condition for which it was not prescribed. Do not give FIRMAGON to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about FIRMAGON that is written for health professionals. What are the ingredients in FIRMAGON? Active ingredient: degarelix (as acetate) Inactive ingredient: mannitol MANUFACTURED FOR: FERRING PHARMACEUTICALS INC., PARSIPPANY, NJ 07054 Manufactured in Germany For more information, go to www.FIRMAGON.com or call 1-888-337-7464. This Patient Information has been approved by the U.S. Food and Drug Administration. 02/2020"],"clinical_pharmacology_table":["
Figure 1: Plasma Testosterone Levels from Day 0 to 364 for Degarelix 240 mg/80 mg (Median with Interquartile Ranges)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Females and males of reproductive potential: FIRMAGON may impair fertility ( 8.3 ) Patients with severe liver or kidney dysfunction have not been studied and caution is therefore warranted ( 8 ) 8.1 Pregnancy Risk Summary The safety and efficacy of FIRMAGON have not been established in women. Based on findings in animal studies and mechanism of action, FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman [ see Clinical Pharmacology (12.1) ]. There are no human data on the use of FIRMAGON in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicity studies in rats and rabbits, oral administration of degarelix during organogenesis caused embryo-fetal lethality and abortion as well as increased post-implantation loss and decreased the number of live fetuses in animals at doses less than the clinical loading dose based on body surface area ( see Data ). Advise pregnant patients and females of reproductive potential of the potential risk to the fetus. Data Animal Data When degarelix was given to rabbits during early organogenesis at doses of 0.002 mg/kg/day (about 0.02% of the clinical loading dose based on body surface area), there was an increase in early post-implantation loss. Degarelix given to rabbits during mid and late organogenesis at doses of 0.006 mg/kg/day (about 0.05% of the clinical loading dose based on body surface area) caused embryo/fetal lethality and abortion. When degarelix was given to female rats during early organogenesis, at doses of 0.0045 mg/kg/day (about 0.036% of the clinical loading dose based on body surface area), there was an increase in early post-implantation loss. When degarelix was given to female rats during mid and late organogenesis, at doses of 0.045 mg/kg/day (about 0.36% of the clinical loading dose based on body surface area), there was an increase in the number of minor skeletal abnormalities and variants. 8.2 Lactation The safety and efficacy of FIRMAGON have not been established in females. There are no data on the presence of degarelix in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are present in human milk and because of the potential for serious adverse reactions in a breastfed child from degarelix, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother. 8.3 Females and Males of Reproductive Potential Infertility Based on findings in animals and mechanism of action, degarelix may impair fertility in males and females of reproductive potential [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Of the total number of subjects in clinical studies of FIRMAGON, 82% were age 65 and over, while 42% were age 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. 8.6 Renal Impairment No pharmacokinetic studies in renally impaired patients have been conducted. At least 20-30% of a given dose of degarelix is excreted unchanged in the urine. A population pharmacokinetic analysis of data from the randomized study demonstrated that there is no significant effect of mild renal impairment [creatinine clearance (CrCL) 50-80 mL/min] on either the degarelix concentration or testosterone concentration. Data on patients with moderate or severe renal impairment is limited and therefore degarelix should be used with caution in patients with CrCL < 50 mL/min. 8.7 Hepatic Impairment Patients with hepatic impairment were excluded from the randomized trial. A single dose of 1 mg degarelix administered as an intravenous infusion over 1 hour was studied in 16 non-prostate cancer patients with either mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. Compared to non-prostate cancer patients with normal liver function, the exposure of degarelix decreased by 10% and 18% in patients with mild and moderate hepatic impairment, respectively. Therefore, dose adjustment is not necessary in patients with mild or moderate hepatic impairment. However, since hepatic impairment can lower degarelix exposure, it is recommended that in patients with hepatic impairment testosterone concentrations should be monitored on a monthly basis until medical castration is achieved. Once medical castration is achieved, an every-other-month testosterone monitoring approach could be considered. Patients with severe hepatic dysfunction have not been studied and caution is therefore warranted in this group."],"dosage_and_administration_table":["
Table 1: FIRMAGON Recommended Dosages
Starting DosageMaintenance Dosage – Administered once every 28 days
240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mLThe first maintenance dose should be given 28 days after the starting dose.80 mg given as one subcutaneous injection at a concentration of 20 mg/mL
","
FIRMAGON 240 mg Starting Dose Kit contains:2 vials containing the 120 mg FIRMAGON powder (a)2 syringes containing Sterile Water for Injection, USP (b)2 vial adapters (c)2 25 gauge × 1 inch injection needles (d)2 plunger rods (e)
FIRMAGON 80 mg Maintenance Dose Kit contains:1 vial containing the 80 mg FIRMAGON powder (f)1 syringe containing Sterile Water for Injection, USP (g)1 vial adapter (h)1 25 gauge × 1 inch injection needle (i)1 plunger rod (j)
In addition the healthcare professional will need:gloves (k)alcohol pads (l)a clean, flat surface (m) to work on, like a tablea sharps disposal container (n) for throwing away your used needles and syringes. See "Disposing used needles and syringes" at the end of these instructions.
","
Step 1: Attaching the vial adaptor to the vialThoroughly wash your hands using soap and water and put on a pair of clean gloves.Place all the supplies required on a clean surface.Check that there is powder in the FIRMAGON vial and that the Sterile Water for Injection, USP is clear and free from particles.IMPORTANT: DO NOT USE if there is no powder in the vial or the Sterile Water for Injection, USP is discolored.
Uncap the vial containing the FIRMAGON powder (o).Wipe the vial rubber stopper with an alcohol pad.IMPORTANT: Do not touch the top of the vial after wiping.
Peel off the seal from the vial adaptor cover.IMPORTANT: Do not touch the vial adapter.Firmly press the vial adaptor (p) onto the vial containing the FIRMAGON powder until the adaptor snaps into place.
Pull the vial adaptor cover off the vial.
Step 2: Assembling the syringeInsert the plunger rod (q) into the prefilled syringe containing Sterile Water for Injection, USP (r) and screw the plunger rod clockwise to tighten.IMPORTANT: Do not pull the back stopper (flange) (s) off the syringe. NOTE: You will only feel light resistance screwing the plunger rod in position.
Step 3: Transferring Sterile Water for Injection, USP from the syringe to the vialUnscrew the gray syringe plug (t) attached to the Luer lock adaptor on the syringe.IMPORTANT: Do not pull off the Luer lock adaptor (u).
Carefully twist the prefilled syringe containing Sterile Water for Injection, USP onto the vial adapter on the FIRMAGON powder vial, until it is tight.IMPORTANT: Be careful not to over twist the syringe.
Press the plunger slowly to transfer all the Sterile Water for Injection, USP from the syringe to the FIRMAGON powder vial.
Step 4: Preparing the reconstituted injectionWith the syringe still attached to the vial adaptor, swirl gently until the liquid is clear with no powder or visible particles.IMPORTANT:Do not shake the vial as this will cause bubbles.Reconstitute just prior to administration.NOTE: If the powder adheres to the side of the vial, tilt the vial slightly. A ring of small air bubbles on the surface of the liquid is acceptable. Reconstitution time can take up to 15 min but usually takes a few minutes.
Step 5: Transferring the liquid to the syringeTurn the vial completely upside down and pull down the plunger to withdraw all of the reconstituted liquid from the vial to the syringe.Tap the syringe gently with your fingers to raise air bubbles in the syringe tip.Press the plunger to the line marked on the syringe to expel all air bubbles.
Step 6: Preparing the syringe for injectionHolding the vial adaptor detach the syringe from the vial by unscrewing the syringe from the vial adaptor.NOTE: Reconstitute just prior to administration.
While holding the syringe with the tip pointing up, screw the injection needle (v) clockwise (right) onto the syringe.
Step 7: Preparing the patientSelect one of the four available injection sites on the abdomen.IMPORTANT:
Do not inject in areas where the patient will be exposed to pressure, such as area around the belt of the waistband or close to the ribs.Vary the injection site periodically during treatment to minimize discomfort to the patient.
Clean the injection site with an alcohol pad.
Step 8: Performing the injectionMove the needle shield (w) away from the needle and carefully remove the needle cover (x).
Pinch and elevate the skin of the abdomen.Insert the needle into the skin at a 45 degree angle all the way to the hub.Do not inject into a vein or muscle. Gently pull back the plunger to check if blood is aspirated.IMPORTANT: If blood appears in the syringe, the product should not be injected. Discontinue the injection and discard the syringe and the needle (reconstitute a new dose for the patient).Perform a slow, deep subcutaneous injection over 30 seconds.
Remove the needle and then release the skin.IMPORTANT: Do not rub the injection site after retracting the needle.
Step 9: Locking the needle into the shieldPosition the needle shield approximately 45 degrees to a flat surface.Press down with a firm, quick motion until a distinct, audible "click" is heard.
Visually confirm that the needle is fully engaged under the lock (y).IMPORTANT: Syringe is for single use only. Do not reuse the syringe and needle.
Step 10: Advising the patientInstruct the patient not to rub or scratch the injection site.Inform that some patients may feel a lump at the injection site and experience redness, soreness and discomfort for a few days after the injection.
"],"spl_patient_package_insert_table":["
trouble breathing or wheezingsevere itchingswelling of your face, lips, mouth, or tongue
","
injection site pain, redness, and swellinghot flashesweight gainincrease in some liver enzymes
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 240 mg Kit Carton NDC 55566-8403-1 FERRING PHARMACEUTICALS FIRMAGON ® 240 mg* (degarelix for injection) *240 mg dose administered from two vials each containing 120 mg For single use subcutaneous injection only Discard unused portion Kit contents: 2 vials each with 120 mg powder for injection 2 syringes with Sterile Water for Injection, USP for reconstitution/administration 2 vial adapters 2 administration needles Starting Dose Rx only PRINCIPAL DISPLAY PANEL - 240 mg Kit Carton","PRINCIPAL DISPLAY PANEL - 80 mg Kit Carton NDC 55566-8303-1 FERRING PHARMACEUTICALS FIRMAGON ® 80 mg (degarelix for injection) For single use subcutaneous injection only Discard unused portion Kit contents: 1 vial with 80 mg powder for injection 1 syringe with Sterile Water for Injection, USP for reconstitution/administration 1 vial adapter 1 administration needle Maintenance Dose (28 Days) Rx only PRINCIPAL DISPLAY PANEL - 80 mg Kit Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Degarelix was administered subcutaneously to rats every 2 weeks for 2 years at doses of 2, 10 and 25 mg/kg (about 9, 45 and 120% of the recommended human loading dose on a mg/m 2 basis). Long term treatment with degarelix at 25 mg/kg caused an increase in the combined incidence of benign hemangiomas plus malignant hemangiosarcomas in females. Degarelix was administered subcutaneously to mice every 2 weeks for 2 years at doses of 2, 10 and 50 mg/kg (about 5, 22 and 120% of the recommended human loading dose (240 mg) on a mg/m 2 basis). There was no statistically significant increase in tumor incidence associated with this treatment. Degarelix did not cause genetic damage in standard in vitro assays (bacterial mutation, human lymphocyte chromosome aberration) nor in in vivo rodent bone marrow micronucleus tests. Single degarelix doses of ≥ 1 mg/kg (about 5% of the clinical loading dose on a mg/m 2 basis) caused reversible infertility in male rats. Single doses of ≥ 0.1 mg/kg (about 0.5% of the clinical loading dose on a mg/m 2 basis) caused a decrease in fertility in female rats."]},"tags":[{"label":"Gonadotropin Releasing Hormone Receptor Antagonist","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"L02BX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Advanced Prostatic Carcinoma","category":"indication"},{"label":"Ferring","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"377 reports"},{"date":"","signal":"INJECTION SITE PAIN","source":"FDA FAERS","actionTaken":"350 reports"},{"date":"","signal":"HOT FLUSH","source":"FDA FAERS","actionTaken":"311 reports"},{"date":"","signal":"INJECTION SITE ERYTHEMA","source":"FDA FAERS","actionTaken":"287 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"210 reports"},{"date":"","signal":"INJECTION SITE SWELLING","source":"FDA FAERS","actionTaken":"205 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"195 reports"},{"date":"","signal":"PRODUCT STORAGE ERROR","source":"FDA FAERS","actionTaken":"177 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"164 reports"},{"date":"","signal":"PROSTATIC SPECIFIC ANTIGEN INCREASED","source":"FDA FAERS","actionTaken":"163 reports"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"}],"commonSideEffects":[{"effect":"Prostatic specific antigen increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site erythema","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site induration","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site swelling","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Product storage error","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hot flush","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Interstitial lung disease","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Osteonecrosis of jaw","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site cellulitis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site mass","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site nodule","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Injection site reaction","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Metastases to bone","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Prostatic specific antigen abnormal","drugRate":"LLR 74","severity":"common","_validated":true}],"contraindications":["Chronic heart failure","Congenital long QT syndrome","Disease of liver","Hypokalemia","Hypomagnesemia","Liver function tests abnormal","Osteopenia","Pregnancy, function","Prolonged QT interval","Torsades de pointes"]},"trials":[],"aliases":[],"company":"Ferring","patents":[{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2032","useCode":"U-1895","territory":"US","drugProduct":false,"patentNumber":"9415085","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Feb 10, 2029","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"9579359","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Feb 20, 2029","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"12514898","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2032","useCode":"U-1895","territory":"US","drugProduct":false,"patentNumber":"10695398","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Feb 20, 2029","useCode":"U-4417","territory":"US","drugProduct":false,"patentNumber":"12533387","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Feb 10, 2029","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"10973870","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Feb 10, 2029","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"10729739","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2032","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"11766468","drugSubstance":false},{"applNo":"N022201","source":"FDA Orange Book","status":"Active","expires":"Apr 27, 2032","useCode":"U-1978","territory":"US","drugProduct":false,"patentNumber":"11826397","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=degarelix","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:46:35.647586+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:46:35.647312+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:46:48.110388+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:46:33.931950+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=degarelix","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:46:48.865991+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:46:32.733899+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:46:50.395340+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL415606/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:46:49.351037+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA022201","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:46:32.733915+00:00"}},"allNames":"firmagon","offLabel":[],"synonyms":["degarelix","firmagon","degarelix acetate"],"timeline":[{"date":"2008-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from FERRING to Ferring"},{"date":"2008-12-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ferring)"},{"date":"2012-06-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Astellas Pharma Inc.)"}],"aiSummary":"Firmagon (degarelix) is a small molecule gonadotropin-releasing hormone receptor antagonist developed by FERRING and currently owned by Ferring. It targets the gonadotropin-releasing hormone receptor to treat advanced prostatic carcinoma. Firmagon was FDA approved in 2008 and is still a patented product. Key safety considerations include its potential to cause injection site reactions and changes in liver function. It has a half-life of 18.6 hours.","approvals":[{"date":"2008-12-24","orphan":false,"company":"FERRING","regulator":"FDA"},{"date":"2012-06-26","orphan":false,"company":"Astellas Pharma Inc.","regulator":"PMDA"}],"brandName":"Firmagon","ecosystem":[{"indication":"Advanced Prostatic Carcinoma","otherDrugs":[{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"},{"name":"estradiol cypionate","slug":"estradiol-cypionate","company":"Pharmacia And Upjohn"},{"name":"estradiol valerate","slug":"estradiol-valerate","company":"Par Sterile Products"},{"name":"goserelin","slug":"goserelin","company":"Astrazeneca"}],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"}],"moaClass":"Gonadotropin Releasing Hormone Receptor Antagonists","modality":"Small Molecule","drugClass":"Gonadotropin Releasing Hormone Receptor Antagonist","explanation":"Think of it like a lock and key. Gonadotropin-releasing hormone is the key that unlocks the pituitary gland to produce testosterone. Firmagon is a key that blocks the lock, preventing the hormone from working and reducing testosterone levels.","oneSentence":"Firmagon works by blocking the action of gonadotropin-releasing hormone on the pituitary gland, which reduces testosterone production.","technicalDetail":"Firmagon binds to the gonadotropin-releasing hormone receptor, competitively inhibiting the action of gonadotropin-releasing hormone and subsequently reducing the release of gonadotropins, which in turn decreases testosterone production."},"commercial":{"launchDate":"2008","_launchSource":"DrugCentral (FDA 2008-12-24, FERRING)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4379","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=degarelix","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=degarelix","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:30:55.739555","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:55.471804+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"abarelix","drugSlug":"abarelix","fdaApproval":"2003-11-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"abiraterone acetate","drugSlug":"abiraterone-acetate","fdaApproval":"2011-04-28","patentExpiry":"May 20, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"relugolix","drugSlug":"relugolix","fdaApproval":"2020-12-18","patentExpiry":"Sep 29, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"degarelix","indications":{"approved":[{"name":"Advanced Prostatic Carcinoma","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Ferring","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"abarelix","brandName":"abarelix","genericName":"abarelix","approvalYear":"2003","relationship":"same-class"},{"drugId":"abiraterone-acetate","brandName":"abiraterone acetate","genericName":"abiraterone acetate","approvalYear":"2011","relationship":"same-class"},{"drugId":"relugolix","brandName":"relugolix","genericName":"relugolix","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04633252","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":["Cancer Of Prostate","Prostate Neoplasms"],"enrollment":86,"completionDate":"2026-12-31"},{"nctId":"NCT06282588","phase":"PHASE2,PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":["Prostate Cancer"],"enrollment":493,"completionDate":"2030-12-31"},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":["Prostate Cancer (Post Prostatectomy)","Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Androgen Deprivation Therapy","Lymph Node Positive"],"enrollment":374,"completionDate":"2038-12-31"},{"nctId":"NCT07335796","phase":"PHASE2","title":"A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-09","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2030-01-09"},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":60,"completionDate":"2034-06-01"},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":["Prostate Cancer"],"enrollment":1538,"completionDate":"2025-09-04"},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":["Prostate Cancer","Localized Prostate Carcinoma"],"enrollment":50,"completionDate":"2030-10"},{"nctId":"NCT06066437","phase":"PHASE1,PHASE2","title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-29","conditions":["Prostate Cancer"],"enrollment":6,"completionDate":"2027-12-31"},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":["Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":804,"completionDate":"2032-12-31"},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":["Metastatic Prostate Cancer","Non-metastatic Prostate Cancer","Prostate Cancer"],"enrollment":9,"completionDate":"2026-06-01"},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":["Prostate Adenocarcinoma","Recurrent Prostate Carcinoma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":["mHSPC","mHNPC","Prostate Cancer Adenocarcinoma"],"enrollment":40,"completionDate":"2027-06"},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":["mCRPC"],"enrollment":10,"completionDate":"2028-06"},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":61,"completionDate":"2027-09"},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":["Metastatic Castration Sensitive Prostate Cancer (mCSPC)","Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":1083,"completionDate":"2024-04-10"},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":["Prostate Cancer"],"enrollment":392,"completionDate":"2031-04-16"},{"nctId":"NCT04989946","phase":"PHASE1,PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":["Prostate Cancer"],"enrollment":60,"completionDate":"2028-12"},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":70,"completionDate":"2027-08-23"},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":["Hormone Sensitive Prostate Cancer","Prostate Adenocarcinoma","Metastasis Prostate Adenocarcinoma"],"enrollment":60,"completionDate":"2026-06-30"},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":["Metastatic Castration Sensitive Prostate Cancer"],"enrollment":25,"completionDate":"2028-11"},{"nctId":"NCT03070886","phase":"PHASE2,PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":["Stage I Prostate Adenocarcinoma AJCC v7","Stage II Prostate Adenocarcinoma AJCC v7","Stage III Prostate Adenocarcinoma AJCC v7"],"enrollment":612,"completionDate":"2025-10-31"},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2029-11-30"},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":["Prostate Adenocarcinoma"],"enrollment":2050,"completionDate":"2026-11-11"},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":["Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":2753,"completionDate":"2033-12-31"},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":["Leukemia","Multiple Myeloma","Myelodysplastic Syndrome","Non-Hodgkin's Lymphoma"],"enrollment":82,"completionDate":"2026-12"},{"nctId":"NCT05501704","phase":"PHASE2","title":"ETHAN - ET for Male BC","status":"RECRUITING","sponsor":"Jose Pablo Leone","startDate":"2023-10-11","conditions":["Male Breast Cancer","Hormone Receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":60,"completionDate":"2036-04-01"},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":106,"completionDate":"2028-11-24"},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":["Prostate Cancer"],"enrollment":68,"completionDate":"2030-11-14"},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":["Recurrent Castration-Sensitive Prostate Carcinoma","Recurrent Prostate Cancer","Castration-resistant Prostate Cancer","Biochemically Recurrent Prostate Carcinoma"],"enrollment":532,"completionDate":"2029-05-31"},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2028-12-31"},{"nctId":"NCT05241860","phase":"PHASE2","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-11-21","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":79,"completionDate":"2033-09-01"},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":["Prostate Cancer"],"enrollment":504,"completionDate":"2025-06-25"},{"nctId":"NCT00117286","phase":"PHASE2,PHASE3","title":"Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2005-03","conditions":["Prostate Cancer"],"enrollment":57,"completionDate":"2009-11"},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":["Prostatic Neoplasms"],"enrollment":979,"completionDate":"2024-08-13"},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":["Metastatic Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":112,"completionDate":"2027-12-30"},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":["Prostate Cancer","Stage IV Prostate Cancer"],"enrollment":32,"completionDate":"2028-07"},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":["Prostate Cancer","Cancer of the Prostate"],"enrollment":28,"completionDate":"2030-07-25"},{"nctId":"NCT03069937","phase":"PHASE2","title":"Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-03-01","conditions":["Metastatic Prostatic Adenocarcinoma"],"enrollment":52,"completionDate":"2024-12-11"},{"nctId":"NCT04787744","phase":"PHASE2,PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":["Prostate Cancer","Oligometastasis","Oligorecurrence","Recurrent Prostate Cancer","Metastatic Prostate Cancer","De Novo Prostate Cancer"],"enrollment":464,"completionDate":"2029-03-30"},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":["High Risk Prostate Carcinoma","Localized Prostate Adenocarcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8"],"enrollment":0,"completionDate":"2028-06-01"},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":["Prostate Cancer"],"enrollment":61,"completionDate":"2036-12"},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":50,"completionDate":"2031-08-30"},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":["Castration Levels of Testosterone","Metastatic Prostatic Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":1273,"completionDate":"2031-10-01"},{"nctId":"NCT07142967","phase":"NA","title":"Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-08-15","conditions":["Intraprostatic Prostate Cancer"],"enrollment":28,"completionDate":"2029-08-02"},{"nctId":"NCT02020070","phase":"PHASE2","title":"Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-12-18","conditions":["Metastatic Castration Sensitive Prostate Cancer"],"enrollment":16,"completionDate":"2026-12"},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":["Metastatic Castration-Resistant Prostate Cancer","Metastatic Castration-Sensitive Prostate Cancer","Non-Metastatic Castration-Resistant Prostate Cancer"],"enrollment":48,"completionDate":"2024-05-28"},{"nctId":"NCT01990196","phase":"PHASE2","title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2014-09-23","conditions":["Prostate Cancer"],"enrollment":45,"completionDate":"2026-09-30"},{"nctId":"NCT04391556","phase":"PHASE2","title":"Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-09-14","conditions":["Prostate Adenocarcinoma"],"enrollment":57,"completionDate":"2024-04-03"},{"nctId":"NCT04301414","phase":"EARLY_PHASE1","title":"Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-02-25","conditions":["Prostate Cancer"],"enrollment":26,"completionDate":"2025-03-13"},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":["Adenocarcinoma of the Prostate","Recurrent Prostate Cancer","Stage III Prostate Cancer","Stage IV Prostate Cancer"],"enrollment":19,"completionDate":"2024-07-18"},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":["Prostate Cancer"],"enrollment":300,"completionDate":"2026-03-31"},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":["Prostate Adenocarcinoma"],"enrollment":25,"completionDate":"2026-02-04"},{"nctId":"NCT03689699","phase":"PHASE1,PHASE2","title":"Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mark Stein","startDate":"2018-10-11","conditions":["Prostate Cancer","Adenocarcinoma of the Prostate"],"enrollment":59,"completionDate":"2026-01"},{"nctId":"NCT03951831","phase":"PHASE2","title":"REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mark Stein","startDate":"2019-05-16","conditions":["Prostate Cancer Metastatic"],"enrollment":26,"completionDate":"2028-04"},{"nctId":"NCT01220869","phase":"PHASE3","title":"A Study of Degarelix in Taiwanese Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-12","conditions":["Prostate Cancer"],"enrollment":110,"completionDate":"2012-10"},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":["Prostate Adenocarcinoma","Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer"],"enrollment":146,"completionDate":"2026-05-17"},{"nctId":"NCT05057546","phase":"PHASE4","title":"Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-11-22","conditions":["Menopause","Estrogen Deficiency","Women","Aging"],"enrollment":55,"completionDate":"2025-07-28"},{"nctId":"NCT05839119","phase":"PHASE1","title":"Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-10-02","conditions":["Urothelial Carcinoma Bladder","Androgen Receptor Positive"],"enrollment":32,"completionDate":"2032-01-01"},{"nctId":"NCT05917860","phase":"PHASE1","title":"Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2023-07-18","conditions":["Localized Prostate Carcinoma","Castration-Naive Prostate Cancer","Intermediate Risk Prostate Cancer","Prostate Cancer"],"enrollment":15,"completionDate":"2030-01-31"},{"nctId":"NCT01994239","phase":"PHASE2","title":"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-12","conditions":["Adenocarcinoma of Prostate"],"enrollment":120,"completionDate":"2025-03"},{"nctId":"NCT02799706","phase":"PHASE3","title":"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-09-25","conditions":["Prostate Cancer"],"enrollment":885,"completionDate":"2026-06-30"},{"nctId":"NCT01261572","phase":"PHASE2","title":"Study to Find Maintenance Dose for Periodic Administration of ASP3550","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-12","conditions":["Prostatic Neoplasms"],"enrollment":155,"completionDate":"2012-04-24"},{"nctId":"NCT06218667","phase":"PHASE1,PHASE2","title":"A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-01-11","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":"2027-01"},{"nctId":"NCT01964170","phase":"PHASE3","title":"A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-08-13","conditions":["Prostate Cancer"],"enrollment":234,"completionDate":"2016-08-08"},{"nctId":"NCT01542021","phase":"NA","title":"Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-02-24","conditions":["Prostate Cancer","Prostatic Adenocarcinoma"],"enrollment":41,"completionDate":"2024-09-30"},{"nctId":"NCT05181800","phase":"","title":"FIRMAGON® Intensive Drug Monitoring","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-08-20","conditions":["Prostate Cancer"],"enrollment":1454,"completionDate":"2022-12-31"},{"nctId":"NCT03056638","phase":"PHASE3","title":"Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-03-28","conditions":["Prostate Cancer"],"enrollment":56,"completionDate":"2023-08-16"},{"nctId":"NCT03080116","phase":"PHASE2","title":"Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-03-28","conditions":["Prostate Cancer","Neoadjuvant Therapy","Androgen Antagonists","Prostatectomy"],"enrollment":90,"completionDate":"2024-07-01"},{"nctId":"NCT06264882","phase":"PHASE4","title":"Cardiometabolic Consequences of the Loss of Ovarian Function","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-06-01","conditions":["Menopause","Estrogen Deficiency","Aging","Adiposity"],"enrollment":100,"completionDate":"2028-08-31"},{"nctId":"NCT02478775","phase":"NA","title":"Dysregulation of FSH in Obesity: Functional and Statistical Analysis","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-07","conditions":["Obesity","Fertility"],"enrollment":99,"completionDate":"2021-06-30"},{"nctId":"NCT03358563","phase":"EARLY_PHASE1","title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-17","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2022-09-02"},{"nctId":"NCT01851018","phase":"NA","title":"Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2012-05","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2025-06"},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":["Prostate Cancer"],"enrollment":39,"completionDate":"2022-12-22"},{"nctId":"NCT01712763","phase":"PHASE3","title":"Degarelix in the Treatment of Endometriosis Recurrence","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2012-11","conditions":["Endometriosis"],"enrollment":360,"completionDate":"2016-03"},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":["Metastatic Castration-sensitive Prostate Cancer"],"enrollment":960,"completionDate":"2022-08-16"},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":["Cancer of Prostate"],"enrollment":202,"completionDate":"2025-12"},{"nctId":"NCT04176081","phase":"PHASE2","title":"Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-07-02","conditions":["Prostate Cancer"],"enrollment":208,"completionDate":"2028-12"},{"nctId":"NCT04043520","phase":"PHASE4","title":"Bioenergetic Effects of Aging and Menopause (BEAM)","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2019-09-24","conditions":["Menopause","Obesity, Abdominal","Aging","Weight Gain"],"enrollment":57,"completionDate":"2024-08-31"},{"nctId":"NCT00819156","phase":"PHASE2","title":"Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2004-02","conditions":["Prostate Cancer"],"enrollment":189,"completionDate":"2005-09"},{"nctId":"NCT00818623","phase":"PHASE2","title":"Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2002-11","conditions":["Prostate Cancer"],"enrollment":172,"completionDate":"2004-10"},{"nctId":"NCT00819247","phase":"PHASE2","title":"The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2001-03","conditions":["Prostate Cancer"],"enrollment":129,"completionDate":"2002-08"},{"nctId":"NCT00930319","phase":"","title":"Effectiveness and Safety of Firmagon®","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-06","conditions":["Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma"],"enrollment":676,"completionDate":"2013-12"},{"nctId":"NCT01377389","phase":"PHASE2","title":"Ipilimumab + Androgen Depravation Therapy in Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-17","conditions":["Prostate Cancer"],"enrollment":30,"completionDate":"2017-04-07"},{"nctId":"NCT06001619","phase":"PHASE4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2022-12-01","conditions":["Prostatic Hyperplasia","Prostate Cancer"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT04897958","phase":"","title":"Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-21","conditions":["Prostate Cancer"],"enrollment":14417,"completionDate":"2021-08-01"},{"nctId":"NCT02015871","phase":"PHASE3","title":"An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2014-01","conditions":["Prostate Cancer"],"enrollment":206,"completionDate":"2017-08-01"},{"nctId":"NCT03947151","phase":"PHASE2","title":"Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-28","conditions":["Invasive Ductal Breast Carcinoma"],"enrollment":8,"completionDate":"2022-08-30"},{"nctId":"NCT04282876","phase":"","title":"Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2020-02-19","conditions":["Bladder Cancer","Radiation Therapy Complication","Quality of Life"],"enrollment":60,"completionDate":"2025-10-31"},{"nctId":"NCT02663908","phase":"PHASE3","title":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-04-19","conditions":["Prostate Cancer"],"enrollment":545,"completionDate":"2021-03-29"},{"nctId":"NCT04397718","phase":"PHASE2","title":"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-07-06","conditions":["COVID-19"],"enrollment":96,"completionDate":"2021-06-08"},{"nctId":"NCT05212857","phase":"PHASE2","title":"Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-04","conditions":["Prostate Cancer"],"enrollment":160,"completionDate":"2024-09"},{"nctId":"NCT02849990","phase":"PHASE2","title":"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-03-09","conditions":["Stage III Prostate Adenocarcinoma AJCC v7","Stage III Prostate Cancer AJCC v7","Stage IV Prostate Adenocarcinoma AJCC v7","Stage IV Prostate Cancer AJCC v7"],"enrollment":22,"completionDate":"2020-12-10"},{"nctId":"NCT02726009","phase":"PHASE4","title":"A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-05","conditions":["Prostate Cancer"],"enrollment":230,"completionDate":"2020-05-15"},{"nctId":"NCT01751451","phase":"PHASE2","title":"3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12-18","conditions":["Prostate Cancer"],"enrollment":124,"completionDate":"2020-09-28"},{"nctId":"NCT02489357","phase":"NA","title":"Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-12-11","conditions":["Stage IV Prostate Cancer"],"enrollment":12,"completionDate":"2017-11-30"},{"nctId":"NCT04248621","phase":"PHASE4","title":"Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients","status":"UNKNOWN","sponsor":"Wonju Severance Christian Hospital","startDate":"2020-01-23","conditions":["Prostatic Neoplasms"],"enrollment":164,"completionDate":"2022-12-31"},{"nctId":"NCT03112226","phase":"NA","title":"Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-02-07","conditions":["Cognitive Impairment","Estrogen Deficiency","Menopause","Endothelial Dysfunction","Vascular Stiffness"],"enrollment":19,"completionDate":"2020-06-21"},{"nctId":"NCT03876912","phase":"NA","title":"The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2019-03-01","conditions":["Prostate Cancer"],"enrollment":35,"completionDate":"2023-03-01"},{"nctId":"NCT04585932","phase":"PHASE2","title":"Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-11-24","conditions":["Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Oligometastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":0,"completionDate":"2021-01-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000178334","MMSL":"164686","NDDF":"012979","UNII":"SX0XJI3A11","VUID":"4028567","CHEBI":"CHEBI:135961","VANDF":"4028567","INN_ID":"8192","RXNORM":"475230","UMLSCUI":"C1455035","chemblId":"CHEMBL415606","ChEMBL_ID":"CHEMBL415606","KEGG_DRUG":"D08635","DRUGBANK_ID":"DB06699","PUBCHEM_CID":"16136245","SNOMEDCT_US":"441758000","IUPHAR_LIGAND_ID":"5585","SECONDARY_CAS_RN":"934246-14-7","MESH_SUPPLEMENTAL_RECORD_UI":"C431566"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2008-","companyName":"Ferring","relationship":"Original Developer"},{"period":"2012","companyName":"Astellas Pharma Inc.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"18.6 hours","clearance":"0.68 mL/min/kg","fractionUnbound":"0.1%","volumeOfDistribution":"0.74 L/kg"},"publicationCount":371,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L02BX02","allCodes":["L02BX02"]},"biosimilarFilings":[],"originalDeveloper":"Ferring","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Ferring","companyId":"ferring","modality":"Small Molecule","firstApprovalDate":"2008","enrichmentLevel":4,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-12-24T00:00:00.000Z","mah":"FERRING","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2012-06-26T00:00:00.000Z","mah":"Astellas Pharma Inc.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-03-25T00:00:00.000Z","mah":"FERRING","brand_name_local":null,"application_number":"NDA022201"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":"EMEA/H/C/006048"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Degarelix Accord","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":24,"withResults":4},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:46:55.471804+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}